UPDATE: Goldman Sachs Raises PT to $16 on NuVasive

Goldman Sachs raises its price target $2 to $16 on Neutral-rated NuVasive

as the company continues to execute in what is an increasingly difficult end-user market. Goldman Sachs says, "4Q2011 results showed market share acceleration in the base US Spine business, as share gains and conversion to minimally invasive surgical (MIS) procedures are still positive trends. In 2012, management's guidance assumes that the base organic growth rate decelerates 300bp (US decelerating 400bp), which we think is appropriately conservative as it relates to end-market trends." NUVA closed at $15.55 a share yesterday.